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Purposes. The serial changes in neointimal tissues were compared between everolimus-eluting stent (EES) and bare-metal stent
(BMS) in the porcine coronary artery using optical coherence tomography (OCT). Methods. Serial (1, 3, and 6 month follow-
up after stent implantation) OCT examinations were performed in 15 swine with 15 BMS- and 15 EES-treated lesions in porcine
coronary arteries. Results. In BMS-implanted lesions, neointimal volume decreased from 7.3mm3 to 6.9mm3 and 6.4mm3 at 1,
3, and 6 months follow-up without statistical significance (𝑃 = 0.369). At the time points of 1, 3, and 6 months, neointimal
tissue appearance was mainly a homogeneous pattern (80.0%, 93.3%, and 100%, resp.), while the other pattern was layered. In
contrast, in EES-implanted lesions, neointimal volume significantly increased from 4.8mm3 to 9.8mm3 between 1 and 3 months
but significantly decreased to 8.6mm3 between 3 and 6 months (𝑃 < 0.001). Between 1 and 3 months, the layered pattern of
neointimal tissue increased from 26.7% to 66.7% but decreased to 20.0% between 3 and 6 months. Conclusions. EES had a biphasic
pattern of neointimal amounts that correlated with changes in neointimal morphology.
1. Introduction
The development of drug-eluting stents (DES) has signifi-
cantly reduced the incidence of in-stent restenosis compared
to bare-metal stents (BMS) [1, 2]. However, even in the DES
era, in-stent restenosis remains a significant clinical problem,
particularly in high-risk patients [3]. Optical coherence
tomography (OCT) is a high-resolution imaging tool that is
ideal for the evaluation of neointimal tissue characteristics
as well as strut coverage of coronary stents [4–6]. The
everolimus-eluting stent (EES) is a second-generation DES
with a target lesion revascularization rate as low as 4.7%
during the 5-year clinical follow-up [7]. However, there
are few studies evaluating temporal changes in neointimal
tissue after EES implantation. The purpose of this study was
to evaluate serial changes in neointimal tissue in stented
segments based on OCT between 1, 3, and 6 months after
EES implantation compared to BMS implantation in normal
porcine coronary arteries.
2. Materials and Methods
2.1. Study Design. A total of 15 swine (weighing 25 to
30 kg) were studied for 6 months to evaluate neointimal
tissue serially following EES implantation. Two stent types
were implanted: EES (Xience Prime, 3.0 × 12mm, Abbott
Vascular, Santa Clara, CA) as a target stent and BMS
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Figure 1: Representative optical coherence tomographic images of neointima. Homogeneous pattern (a) and layered pattern (b).
(Blazer, 3.0 × 13mm, OrbusNeich, Hong Kong) as a control
stent. Each stent was deployed in the left anterior descend-
ing artery or right coronary artery. At the time of stent
deployment, each stent was systematically randomized to
each coronary artery in each animal. Follow-up angiography
with OCT was serially performed 1, 3, and 6 months after
stent implantation. All animals received humane care in
compliance with the Animal Welfare Act and “The Guide
for the Care and Use of Laboratory Animals” formulated
by the Institute of Laboratory Animal Research [8]. This
study was approved by the local institutional animal care
and use committee (Medi Kinetics, MK-IACUC: 111027-0001
and Cardiovascular Production Evaluation Center, Yonsei
University College of Medicine).
2.2. Procedural Description. All animals were premedicated
at least 12 hours before the procedure with 100mg aspirin
and 300mg clopidogrel. Anesthesia was performed via intra-
muscular injection of ketamine (20mg/kg) and xylazine
(2mg/kg). After adequate anesthesia, animals were intubated
and inhaled isoflurane (1-2%) delivered through a precision
vaporizer and a circle absorption breathing system with peri-
odic arterial blood gas monitoring. Under sterile conditions,
arteriotomy of the carotid artery was performed and a 6-Fr
vascular access sheath was introduced into the carotid artery.
Vital signs were continuously monitored using surface elec-
trocardiography and were recorded at approximately 20min
intervals. Unfractionated heparin (5,000 to 10,000 IU) was
administered to maintain activated clotting times of 250 to
300 seconds. Using fluoroscopic guidance, stent implantation
on coronary arteries was performed with a stent-to-artery
ratio of 110% to 120% overstretch for full apposition at pre-
determined sites using conventional techniques. After stent
implantation, carotid arteries were repaired and the incision
site was closed with adequate suture material until the next
use of the carotid arteries. All animals received 100mg aspirin
and 75mg clopidogrel daily after stent implantation. They
were fed a regular diet throughout the duration of the study
[4].
2.3. OCT Procedure and Analyses. OCTwas performed using
the C7-XR imaging systems (LightLab Imaging, Inc., St. Jude
Medical, St. Paul, MN). The OCT catheter was pulled back
at 20mm/s and OCT images were generated at 100 frames/s.
Contrast media were continuously flushed through a guiding
catheter at a rate of 4 to 5mL/s for 3 to 4 seconds. Images were
continuously acquired and stored digitally for subsequent
analyses. All OCT images were analyzed at a core laboratory
(Cardiovascular Research Center, Seoul, Republic of Korea)
by analysts who were blinded to procedural information.
Cross-sectional OCT images were analyzed at 1mm intervals.
Stent and luminal cross-sectional areas (CSA) weremeasured
and neointimal hyperplasia (NIH) CSA was calculated by
subtracting the luminal CSA from the stent CSA. The NIH
CSA percentage was calculated as the NIH CSA divided
by the stent CSA. NIH thickness was measured as the
distance between the strut with a line perpendicular to the
neointima and the endoluminal surface of the neointima.
The NIH volume was calculated as NIH CSA × length. The
maximal NIH site with 2mm proximal and distal adjacent
portion in the stented segment was serially compared to the
corresponding segment based on the maximal NIH site at
the 1 month follow-up. Serial comparisons were performed
by matching the length from the stent edge and anatomical
features, such as side branch.
If themean neointimal thickness was ≥20𝜇m, neointimal
tissue characteristics were qualitatively classified as homo-
geneous, heterogeneous, or layered pattern. Homogeneous
patterns were defined as uniform optical neointima tissue
properties without focal variation in backscattering pattern.
Heterogeneous patterns were defined as focal changes in
optical properties and various backscattering patterns. Lay-
ered pattern refers to concentric layers with different optical
properties, namely, an adluminal high scattering layer and
abluminal low scattering layer (Figure 1) [9].
2.4. Quantitative Angiographic Analyses. Quantitative coro-
nary angiography analyses were performed using an offline
computerized quantitative coronary angiographic system
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Figure 2: Serial changes in neointimal volume at the segment with maximal amounts of neointimal hyperplasia at the 1-month follow-up.
(CASS System, PieMedical Imaging,Maastricht,TheNether-
lands) in an independent core laboratory (Cardiovascular
Research Center, Seoul, Korea).Theminimal lumen diameter
and reference diameters of treated coronary lesions were
measured in the view with the narrowest lumen and the least
amount of foreshortening.
2.5. Statistical Analyses. Continuous variables are expressed
as amedianwith interquartile range (IQR).Wilcoxon signed-
rank tests or Friedman tests were used to compare variables
in a longitudinal manner. Categorical variables are expressed
as both numbers and percentages and were compared using
Fisher’s exact tests. Data were analyzed using SPSS 18.0
software for Windows (SPSS, Chicago, IL). A 𝑃 value < 0.05
was considered statistically significant.
3. Results and Discussion
3.1. Results. EESwas implanted in eight left anterior descend-
ing arteries and seven right coronary arteries, whereas BMS
was deployed in seven left anterior descending arteries and
eight right coronary arteries. Balloon-to-artery ratio was
similar between two groups (1.11±0.06 in BMS versus 1.14±
0.04 in EES, 𝑃 = 0.189). Serial OCT evaluation of NIH
was assessed in a total of 15 BMS- and 15 EES-implanted
into the coronary arteries of 15 animals after 1, 3, and 6
months. Serial angiographic and OCT findings are shown
in Table 1. Based on analyses of whole stented segments
in BMS, the mean NIH thickness was maximal at 1 month
(190.4 𝜇m, IQR 127.0–243.9𝜇m) and decreased at 3 and 6
months (182.2 𝜇m, IQR 131.9–229.4𝜇m and 169.8 𝜇m, IQR
112.7–211.1 𝜇m, 𝑃 = 0.189). However, in EES, it was maximal
at 3 months (276.5𝜇m, IQR 172.2–428.1𝜇m) and decreased
at 6 months (269.6𝜇m, IQR 199.9–396.4 𝜇m, 𝑃 = 0.100). For
analyses of maximal NIH segments at 1 month, serial changes
in NIH volume after BMS and EES are shown in Figure 2 and
Table 2. In BMS-implanted lesions, NIH volume decreased
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Figure 3: Serial changes in neointimal patterns at the segment with
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from 7.3mm3 (IQR 4.7–8.4mm3) at the 1-month follow-up to
6.9mm3 (IQR 4.6–8.2mm3) and 6.4mm3 (IQR 4.3–7.4mm3)
after 3 and 6 months, respectively (𝑃 = 0.369). At the
different time points of 1, 3, and 6 months, neointimal tissue
appearance was predominantly the homogeneous pattern
(80.0%, 93.3%, and 100%, resp.), while the other pattern was
layered (Figure 3). In contrast, in EES-implanted lesions,
NIH volume significantly increased from 4.8mm3 (IQR 4.1–
7.6mm3) to 9.8mm3 (IQR 5.7–15.1mm3) between 1 and 3
months (𝑃 < 0.001) but significantly decreased to 8.6mm3
(IQR 6.0–11.2mm3) between 3 and 6 months (𝑃 = 0.007)
(𝑃 < 0.001 between 1 and 6 months) (Figure 2). Between
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Table 2: Optical coherence tomographic findings of the maximum neointima site at 1, 3, and 6 months after stent implantation.
Bare-metal stent (𝑛 = 15) Everolimus-eluting stent (𝑛 = 15)
1 month 3 months 6 months 1 month 3 months 6 months
Quantitative analyses
Stent volume, mm3 24.5(21.4–27.4)
24.3
(21.8–26.9)
23.3
(21.4–26.5)
25.5
(20.7–27.2)
25.5
(20.4–27.6)
24.7
(19.9–27.9)
Lumen volume, mm3 16.7(14.1–20.2)
17.5
(15.7–20.6)
17.6
(14.4–20.8)
18.7
(16.5–21.4)
12.6
(11.5–17.6)
15.5
(13.3–18.3)
Neointima volume, mm3 7.3 (4.7–8.4) 6.9 (4.6–8.2) 6.4 (4.3–7.4) 4.8 (4.1–7.6) 9.8 (5.7–15.1) 8.6 (6.0–11.2)
Qualitative analyses
Homogeneous, % 12 (80.0) 14 (93.3)∗ 15 (100) 11 (73.3) 5 (33.3) 12 (80.0)
Layered, % 3 (20.0) 1 (6.7)∗ 0 (0) 4 (26.7) 10 (66.7) 3 (20.0)
∗
𝑃 < 0.05, comparing bare-metal stent with everolimus-eluting stent.
Layered
Homogeneous
1 3 6 1 3 6
Bare-metal stent Everolimus-eluting stent
(months) (months)
Figure 4: Evolution of serial changes in neointimal patterns in bare-metal stent and everolimus-eluting stent.
1 and 3 months, the layered pattern of neointima increased
from 26.7% to 66.7% but decreased to 20.0% between 3 and 6
months (Figures 3 and 4). Figures 5 and 6 show typical OCT
images of serial NIH changes in BMS- and EES-implanted
coronary arteries, respectively.
3.2. Discussion. Using serial (1, 3, and 6 months follow-
up) OCT in the nonatherosclerotic porcine coronary artery
model, the present study showed that (1) a biphasic neointi-
mal response of EES consisted of an early progression phase
and late regression phase and (2) quantitative neointima
changes correlated with morphological neointima changes
from a layered pattern to a homogeneous pattern.
Serial quantitative neointimal changes of BMS have been
well evaluated in human studies. In BMS, long-term angio-
graphic luminal responses were a triphasic pattern that con-
sisted of a restenosis phase at the early period for 6 months,
a regression phase at the intermediate period between 6
months and 3 years, and a late renarrowing phase after 4 years
[10]. The results of intravascular ultrasound studies were also
consistent with those from a previous angiographic study [11,
12]. One intravascular ultrasound study reported that mean
neointimal CSA significantly decreased from 2.6±1.0 to 2.3±
0.9mm2 between 6 and 24 months after BMS-implantation
[12]. The results from the BMS-implanted lesions in the
current study are in agreement with results from previous
studies [10–12].
However, information regarding long-term serial changes
in neointima following DES implantation was not sufficient.
Sousa et al. first reported after 4-year angiographic follow-up
of 26 sirolimus-eluting stent-treated patients that a temporal
progression of late loss was observed: late loss was 0.08mm
from postintervention to the 1-year follow-up, and it was
−0.03mm from 1- to 2-years and 0.20mm from 2- to 4-years
[13]. In another study with 15 sirolimus-eluting stent-treated
patients, there were no significant changes in stent minimal
lumen diameter based on quantitative coronary angiographic
analyses and no significant deterioration in lumen volume by
intravascular ultrasoundmeasurement between the 6-month
and 2-year follow-up [14]. In substudy of randomizedTAXUS
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Figure 5: Examples of neointimal volume and patterns at the segment with maximal amounts of neointimal hyperplasia at 1, 3, and 6months
following bare-metal stent implantation. NIH, neointimal hyperplasia.
II trial, neointimal volume measured by intravascular ultra-
sound increased significantly from 10.13mm3 at 6 months to
15.11mm3 at 2 years after paclitaxel-eluting stent implantation
(𝑃 = 0.0011) [15]. In 2-year follow-up results of the SPIRIT II
trial, in-stent neointimal volume progressed from 4.13mm3
at 6 months to 8.42mm3 at 2 years after EES implantation
[16].
Quantitative OCT assessment has been well validated.
One study of in vivo OCT comparison with histology in
a rabbit carotid model showed that histological and OCT
measurements of mean NIH thickness were similar and
closely related (𝑟 = 0.85, 𝑃 < 0.001) [17]. OCT and histology
correlated highly for the evaluation of neointimal area (𝑅2 =
0.804), luminal area (𝑅2 = 0.825), and neointimal thickness
(𝑅
2
= 0.789) in a normal porcine coronary model [4]. In
qualitative OCT assessments, neointima with rich smooth
muscle cells and dense collagen fibers has a high backscatter
signal and is shown as high optical intensity, extracellular
matrix or myxomatous tissue, such as proteoglycan or fibrin
rich neointima with few smooth muscle cells, and has a
low backscatter signal and is shown as a lucent signal [18–
20]. Although a homogeneous pattern with a high optical
intensity is usually observed in in-stent restenosis of BMS,
the layered pattern was observed more frequently in in-stent
restenosis of DES [18].The layered pattern consisted of a high
intense inner layerwith smoothmuscle cells and a low intense
outer layer with extracellular material rich lesions [18]. In
current study, heterogeneous patternwas not detected in con-
trast to the previous study [20], which could not be explained
exactly. The previous study used hypercholesterolemic swine
model and different type ofDES (especially, paclitaxel-eluting
stent), which was evident difference compared to our study
[20].
Using intravascular imaging tools, serial follow-up data
beyond 2 years after DES implantation are sparse in clinical
practice as well as in random clinical trials due to the practical
or ethical aspects of clinical practice. However, these data
are very important for understanding the long-term natural
history of DES-treated patients. Considering the findings
that the neointimal growth pattern in porcine coronary stents
after 1 month was compatible with those in human coronary
stents after 6–12 months [21], the results of the present serial
study (1, 3, and 6 months follow-up after stent implantation)
in porcine coronary arteries may be compatible with very late
(beyond approximately 2 or 3 years follow-up) neointimal
responses in DES-treated patients. In the present study, NIH
thickness in the analyses of whole segments and NIH volume
in the analyses of maximal NIH segments in EES-implanted
lesions weremaximal at 3months and decreased at 6months.
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Figure 6: Examples of neointimal volume and patterns at the segment with maximal amounts of neointimal hyperplasia at 1, 3, and 6months
following everolimus-eluting stent implantation. NIH, neointimal hyperplasia.
To the best of our knowledge, this is the first report to show
a biphasic neointimal response of EES-implanted segments,
particularly neointimal regression between 3 and 6 months
in the porcine coronary model. In addition, neointimal
regression occurred with a morphological shift from
a layered pattern to a homogeneous pattern. The mechanism
of the neointimal regression is not clearly understood. Recent
OCT study reported that the evolution of heterogeneous to
homogeneous neointima was observed in lesions with NIH
regression, while the evolution of homogeneous to layered
neointima was detected in lesions with NIH progression
(𝑃 < 0.001) [22]. The present study supports the notion that
neointimal stabilization from immature tissue, such as fibrin
near strut, rich extracellular matrix, and inflammatory cells
to maturation with rich smooth muscle cells, may play a role
in neointimal regression [23].
Limitations. This study is based on the nonatherosclerotic
normolipemic porcine coronarymodel.Therefore, the results
of the present study may need to be interpreted with caution
for clinical practice of DES-treated patients. Although the
diseased porcine animal models have been increasingly
used for the evaluation of DES and provided more similar
biological responses, normolipemic swine coronary artery
is still recommended as the choice of the porcine model to
evaluate tissue response in consensus documents [24, 25].
The comparisons between OCT images with histology were
not performed at each stage of follow-up.
4. Conclusion
This serial OCT study found that EES had a biphasic pattern
(early progression and late regression) of neointimal tissue
that correlated with changes in neointimal morphology.
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